Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

New Low-Cost Rotavirus Vaccine Could Reduce Disease Burden in Developing Countries

By Harvard's School of Public Health | March 29, 2017

A new vaccine for rotavirus was found to be 66.7% effective in preventing severe gastroenteritis caused by the virus, according to a new study from researchers at Harvard T.H. Chan School of Public Health and Epicentre, Paris. Rotavirus is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age each year, or about 450,000 children, with a disproportionate effect in sub-Saharan Africa.

The study will be published in the March 23, 2017 issue of the New England Journal of Medicine.

Rotavirus is the leading cause of acute diarrhea, or severe gastroenteritis, in children. Unlike other causes of diarrhea, improvements in water, sanitation, and hygiene do not prevent rotavirus transmission, therefore vaccination is essential to prevent death and complications from childhood diarrhea.

To make a difference in countries where the rotavirus burden is highest and access to health care is low, vaccines need to be affordable, as well as safe, effective, and heat-stable. Currently there are two rotavirus vaccines, but they are expensive and refrigeration must be maintained throughout the supply chain. In resource-poor countries such as Niger, electricity and refrigeration are often unreliable. The new vaccine is heat-stable, the first of its kind for rotavirus prevention.

“This trial brings a vaccine which is adapted to African settings to those who need it most,” said first author Sheila Isanaka, assistant professor of nutrition at Harvard Chan School. “When the vaccine becomes widely available in Africa, it will help protect millions of the most vulnerable children.”

For the trial, researchers conducted a randomized, placebo-controlled trial in Niger to evaluate the efficacy of BRV-PV, a low-cost, heat-stable vaccine manufactured by Serum Institute of India Pvt Ltd. The researchers recruited 3,508 healthy infants to receive three doses of the vaccine or placebo at 6, 10, and 14 weeks of age. All children included in the trial are monitored in local health centers and receive free health care for two years.

The vaccine has been licensed in India, but approval–known as prequalification– by the World Health Organization is needed before it can be purchased by the United Nations and government agencies. “After the successful clinical trial of this new vaccine, we hope that it can be made available as soon as possible to children in Niger and across Africa,” Isanaka said.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE